LON:MXC Argent BioPharma (MXC) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Argent BioPharma Stock (LON:MXC) 30 days 90 days 365 days Advanced Chart Get Argent BioPharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range 22▼ 2252-Week Range N/AVolume264 shsAverage Volume26,353 shsMarket Capitalization£9.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia.Read More… Receive MXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Argent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address MXC Stock News HeadlinesArgent and AusCann partner to accelerate cannabinoid pharma developmentApril 15, 2025 | msn.comArgent BioPharma Prepares for Major Capital RaisingJanuary 2, 2025 | tipranks.comElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.May 8, 2025 | Brownstone Research (Ad)Argent BioPharma to Delist From London Stock Exchange, Mulls U.S. ListingNovember 29, 2024 | marketwatch.comArgent BioPharma Ltd (RGT)May 9, 2024 | investing.comArgent BioPharma starts trading on OTCQB Venture Market; appoints CFOMay 6, 2024 | au.investing.comArgent BioPharma appoints Dr Shlomo Sadoun to advisory boardApril 14, 2024 | au.investing.comMGC Pharmaceuticals Ltd (MXC)January 30, 2024 | uk.investing.comSee More Headlines MXC Stock Analysis - Frequently Asked Questions How do I buy shares of Argent BioPharma? Shares of MXC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Argent BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Argent BioPharma investors own include Rolls-Royce Holdings plc (RR), Argo Blockchain (ARB), AutoZone (AZO), BP (BP), Chaarat Gold (CGH), Diageo (DGE) and EQTEC (EQT). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPetroleum And Natural Gas Current SymbolLON:MXC CIKN/A Webmgcpharma.com.au Phone61-8-6555-2950FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-17,020,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-58.96% Debt Debt-to-Equity Ratio1,436.12 Current Ratio0.75 Quick RatioN/A Sales & Book Value Annual Sales£1.32 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 4 per share Price / BookN/AMiscellaneous Outstanding Shares43,850,000Free FloatN/AMarket Cap£9.65 million OptionableNot Optionable Beta1.03 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (LON:MXC) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredYour Wealth is Being Erased – Save It Before It’s Gone ForeverWhat If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands o...Hamilton Gold Group | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be la...Porter & Company | SponsoredAm I wrong for thinking this about you?The media says Trump supporters are giving up. But I know the truth: you’re the kind of American who doesn’t f...Colonial Metals | SponsoredNew breed of trader (Wall Street hates us?)Wall Street big wigs and old-money bankers can’t touch this 1 type of stock. And that opens the door for tr...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Argent BioPharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Argent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.